Training and Resources

KEYTRUDA^® (pembrolizumab) in advanced Renal Cell Carcinoma (aRCC)

ascGeneral Itemother|Oncology|Keytruda|RCCpublicationdatetypeofcontent|therapeuticgroup|localproductname|otherdate01250tcm:4244-1157145Treatment modifications for associated Immune Related Adverse Events: advanced Renal Cell Carcinoma (aRCC)/static/mciuk/images/msdc_keytruda_rcc_irae_thumbnail.png/training-resources/keytruda/rcc/irae-management-arcc.xhtml <a href="http://www.msdproduct.co.uk/api/keytruda.pdf" target="_blank" xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance">Prescribing Information</a>rcc/static/mciuk/images/msdc_keytruda_rcc_irae_thumbnail.pngassetIdtcm:4244-1157145pathologiesRenal CancerlocalproductnameKeytrudaglobalproductnameKeytrudakeywordsspecialityexpirationdatepublicationdate2018-05-23codextypeofcontentotherengagementtypeEducateinternationalproductnameareacustomertypetargetaudiencehcptherapeuticgroupOncologyassettypeVideoassetfranchiseOncologyasset_descriptionasset_purposeEducational Contentasset_content_classificationCommercial - Brandedasset_accessibilityAnonymousasset_publisherreadtimehashtagstcm:4244-1158427Materials for patients being treated with Keytruda in combination with Axitinib for aRCC/static/mciuk/images/msdc_keytruda-co-uk_patient_link.pngMaterials for patients being treated with Keytruda in combination with Axitinib for aRCChttps://www.keytruda.co.uk/patient-pages/kidney <a href="http://www.msdproduct.co.uk/api/keytruda.pdf" target="_blank" xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance">Prescribing Information</a>rcc/static/mciuk/images/msdc_keytruda-co-uk_patient_link.pngassetIdtcm:4244-1158427pathologiesRenal CancerlocalproductnameKeytrudaglobalproductnameKeytrudakeywordsspecialityexpirationdatepublicationdate2018-05-23codextypeofcontentotherengagementtypeEducateinternationalproductnameareacustomertypetargetaudiencehcptherapeuticgroupOncologyassettypeVideoassetfranchiseOncologyasset_descriptionasset_purposeEducational Contentasset_content_classificationCommercial - Brandedasset_accessibilityAnonymousasset_publisherreadtimehashtags

Rating

Treatment modifications for associated Immune Related Adverse Events: advanced Renal Cell Carcinoma (aRCC)

Prescribing Information

Rating

Materials for patients being treated with Keytruda in combination with Axitinib for aRCC

Prescribing Information

< Previous 1 Next >

ascGeneral Itemother|Oncology|Keytruda|RCCpublicationdatetypeofcontent|therapeuticgroup|localproductname|otherdate01250tcm:4244-1157145Treatment modifications for associated Immune Related Adverse Events: advanced Renal Cell Carcinoma (aRCC)/static/mciuk/images/msdc_keytruda_rcc_irae_thumbnail.png/training-resources/keytruda/rcc/irae-management-arcc.xhtml <a href="http://www.msdproduct.co.uk/api/keytruda.pdf" target="_blank" xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance">Prescribing Information</a>rcc/static/mciuk/images/msdc_keytruda_rcc_irae_thumbnail.pngassetIdtcm:4244-1157145pathologiesRenal CancerlocalproductnameKeytrudaglobalproductnameKeytrudakeywordsspecialityexpirationdatepublicationdate2018-05-23codextypeofcontentotherengagementtypeEducateinternationalproductnameareacustomertypetargetaudiencehcptherapeuticgroupOncologyassettypeVideoassetfranchiseOncologyasset_descriptionasset_purposeEducational Contentasset_content_classificationCommercial - Brandedasset_accessibilityAnonymousasset_publisherreadtimehashtagstcm:4244-1158427Materials for patients being treated with Keytruda in combination with Axitinib for aRCC/static/mciuk/images/msdc_keytruda-co-uk_patient_link.pngMaterials for patients being treated with Keytruda in combination with Axitinib for aRCChttps://www.keytruda.co.uk/patient-pages/kidney <a href="http://www.msdproduct.co.uk/api/keytruda.pdf" target="_blank" xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance">Prescribing Information</a>rcc/static/mciuk/images/msdc_keytruda-co-uk_patient_link.pngassetIdtcm:4244-1158427pathologiesRenal CancerlocalproductnameKeytrudaglobalproductnameKeytrudakeywordsspecialityexpirationdatepublicationdate2018-05-23codextypeofcontentotherengagementtypeEducateinternationalproductnameareacustomertypetargetaudiencehcptherapeuticgroupOncologyassettypeVideoassetfranchiseOncologyasset_descriptionasset_purposeEducational Contentasset_content_classificationCommercial - Brandedasset_accessibilityAnonymousasset_publisherreadtimehashtags

More information about KEYTRUDA^® (pembrolizumab) in aRCC

Visit product page

Supporting documentation

Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-RCC-00150 | Date of Preparation: July 2020

Join us,

Congratulations!

Training and Resources

KEYTRUDA^® (pembrolizumab) in advanced Renal Cell Carcinoma (aRCC)

Treatment modifications for associated Immune Related Adverse Events: advanced Renal Cell Carcinoma (aRCC)

Materials for patients being treated with Keytruda in combination with Axitinib for aRCC

More information about KEYTRUDA^® (pembrolizumab) in aRCC

Supporting documentation

Join us,

Congratulations!

Training and Resources

KEYTRUDA® (pembrolizumab) in advanced Renal Cell Carcinoma (aRCC)

Treatment modifications for associated Immune Related Adverse Events: advanced Renal Cell Carcinoma (aRCC)

Materials for patients being treated with Keytruda in combination with Axitinib for aRCC

More information about KEYTRUDA® (pembrolizumab) in aRCC

Supporting documentation

KEYTRUDA^® (pembrolizumab) in advanced Renal Cell Carcinoma (aRCC)

More information about KEYTRUDA^® (pembrolizumab) in aRCC